08 Jan 2013, BioSpectrum Bureau , BioSpectrum
Singapore: US-based IntelligentMDx collaborated with Qiagen to design, develop and manufacture several undisclosed CE-marked and FDA-cleared diagnostic tests for use on Qiagen's flagship QIAsymphony RGQ automated platform. Financial terms of the deal have not been disclosed yet. Qiagen has retained the rights to assume manufacturing of the assays, pursuant to volume considerations.
IntelligentMDx's innovative assay development process uses proprietary bioinformatics platform, which allows for efficient design of robust and accurate diagnostics that can be formatted for a variety of real-time PCR platforms.
QIAsymphony is a novel and flexible laboratory workflow automation system for molecular testing that incorporates all workflow steps from biological sampling-to-result generation. This new and complete workflow solution is comprised of modules that can be used either as stand-alone systems or combined into the fully integrated QIAsymphony RGQ system. Through this system, Qiagen provides laboratories with a platform that maximizes their efficiency in the emerging field of molecular diagnostics.
Qiagen is developing a broad range of tests for use on this system. The menu includes infectious disease assays, genetics assays and in particular, companion diagnostics (CDx) that are used to guide the use of medicines in treating patients. QIAGEN markets a menu of more than 20 assays for use on the QIAsymphony system in Europe.
"A key element to improving patient care is ensuring clinical labs have access to the widest range of reliable diagnostic test options for their instrumentation of choice," says Dr Alice Jacobs Nesselrodt, chairman and CEO, IntelligentMDx. "We are extremely pleased to have the opportunity to combine the strengths of IntelligentMDx and Qiagen in order to make new tests available globally to labs utilizing the QIAsymphony RGQ."